Tocilizumab can efficiently prevent bone destruction in patients with recent-onset rheumatoid arthritis

Objectives: To assess whether tocilizumab (TCZ) can prevent bone destruction in patients with recent-onset rheumatoid arthritis (RA). Methods: DAS28-ESR and van der Heijde-modified Sharp score (mTSS) were evaluated in 50 patients who received TCZ within 1 year from the onset of RA. TCZ was consecutively administered during the observation period within the first 2 years. In 15 patients, mTSS could be evaluated at 5 years. Results: The mean DAS28-ESR at baseline, 1, 2, and 5 years was 4.86, 1.29, 1.19, and 1.18, respectively. The change in mTSS (Delta mTSS) between baseline and 2 years was -0.33. The structural remission rates (Delta mTSS/year <= 0.5) were 91.8% and 92.7% during the first and second years, respectively. Only one increase in erosion score was observed in the first year in 2 patients and the erosion score of all patients did not increase in the second year. In 15 patients, the Delta mTSS over 5 years was 0.80, corresponding to 0.16 per year. The structural remission rate at 5 years (Delta mTSS <= 2.5) was 93.3%. The erosion score was 0 in all 15 patients at 5 years, indicating that bone destruction did not become apparent. Conclusion: TCZ can efficiently prevent bone destruction in patients with recent-onset RA.

Automated summary

The study findings suggest that tocilizumab (TCZ) can effectively prevent bone destruction in patients with recent-onset rheumatoid arthritis and maintain sustained structural remission over 5 years.